Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,161,312 papers from all fields of science
Search
Sign In
Create Free Account
ARN-509
Known as:
Androgen Receptor Antagonist ARN-509
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
NCIt Antineoplastic Agent Terminology
Broader (1)
Thiohydantoins
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines
M. Koukourakis
,
Christos Kakouratos
,
+6 authors
A. Giatromanolaki
Anti-Cancer Drugs
2018
Corpus ID: 3859646
Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to…
Expand
2016
2016
The Ongoing Challenges of Targeting the Androgen Receptor.
M. Kolinsky
,
J. D. de Bono
European Urology
2016
Corpus ID: 13182029
Review
2015
Review
2015
[New therapies in metastatic castration resistant prostate cancer].
C. Thibault
,
C. Massard
Bulletin du Cancer
2015
Corpus ID: 116563758
2013
2013
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC).
E. Antonarakis
,
C. Ryan
,
+6 authors
D. Rathkopf
Journal of Clinical Oncology
2013
Corpus ID: 37615039
7 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen…
Expand
2013
2013
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).
E. Antonarakis
,
N. Shore
,
+6 authors
H. Scher
Journal of Clinical Oncology
2013
Corpus ID: 23760692
48 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the…
Expand
2013
2013
Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
Jesal C. Patel
,
B. Maughan
,
A. Agarwal
,
J. Batten
,
Tian-yi Zhang
,
N. Agarwal
Prostate Cancer
2013
Corpus ID: 6080203
Androgen deprivation therapy (ADT) with medical or surgical castration is the mainstay of therapy in men with metastatic prostate…
Expand
2012
2012
A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).
D. Rathkopf
,
N. Shore
,
+15 authors
H. Scher
2012
Corpus ID: 220744896
4548 Background: ARN-509 is a novel small molecule AR antagonist that impairs AR nuclear translocation and binding to DNA…
Expand
2012
2012
Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium…
D. Rathkopf
,
D. Danila
,
+10 authors
H. Scher
Journal of Clinical Oncology
2012
Corpus ID: 22437633
43 Background: In CRPC, androgen receptor (AR) overexpression is associated with resistance to first-generation anti-androgen…
Expand
2012
2012
Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium…
D. Rathkopf
,
D. Danila
,
+10 authors
H. Scher
Journal of Clinical Oncology
2012
Corpus ID: 7360106
43 Background: In CRPC, androgen receptor (AR) overexpression is associated with resistance to first-generation anti-androgen…
Expand
2011
2011
A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).
D. Rathkopf
,
D. Danila
,
+7 authors
H. Scher
Journal of Clinical Oncology
2011
Corpus ID: 36598596
TPS190 Background: The results of molecular profiling studies show that androgen receptor (AR) overexpression is associated with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE